Skip to main content


Cancer Immunology, Immunotherapy

Cancer Immunology, Immunotherapy OnlineFirst articles

24.09.2018 | Original Article

TRPM2 modulates neutrophil attraction to murine tumor cells by regulating CXCL2 expression

In recent years, immune cells were shown to play critical roles in tumor growth and metastatic progression. In this context, neutrophils were shown to possess both pro- and anti-tumor properties. To exert their anti-tumor effect, neutrophils need …

19.09.2018 | Focussed Research Review

The role of CCR5 in directing the mobilization and biological function of CD11b+Gr1+Ly6Clow polymorphonuclear myeloid cells in cancer

Bone marrow (BM) cells of the hematopoietic system, also known as BM-derived leukocytes (BMD), are mobilized from the BM to the blood and then colonize tumor sites. These cells then become key players in either promoting or regulating the …

19.09.2018 | Review

TIGIT: a novel immunotherapy target moving from bench to bedside

Treatment strategies for patients with advanced solid tumors have traditionally been based on three different paradigms: surgery, cytotoxics (chemotherapy or radiation therapy) and targeted therapies. Immunotherapy has emerged as a novel treatment …

19.09.2018 | Original Article Open Access

Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up

Our earlier multicenter randomized controlled trial showed that adjuvant immunotherapy with cytokine-induced killer (CIK) cells resulted in longer recurrence-free survival (RFS) and overall survival (OS) as well in patients who received curative …

18.09.2018 | Original Article Open Access

β-Adrenergic signaling blocks murine CD8+ T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress

Primary and secondary lymphoid organs are heavily innervated by the autonomic nervous system. Norepinephrine, the primary neurotransmitter secreted by post-ganglionic sympathetic neurons, binds to and activates β-adrenergic receptors expressed on …

Aktuelle Ausgaben

Über diese Zeitschrift

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.

In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:

  • “Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.
  • “Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.

CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT),and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).







Weitere Informationen

Neu im Fachgebiet Onkologie




Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.